We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

245 hedge funds and large institutions have $5.8B invested in Avidity Biosciences in 2024 Q3 according to their latest regulatory filings, with 72 funds opening new positions, 86 increasing their positions, 62 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 72 | Existing positions closed: 23

43% more call options, than puts

Call options by funds: $10.7M | Put options by funds: $7.5M

39% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 62

27% more capital invested

Capital invested by funds: $4.57B → $5.8B (+$1.22B)

25% more funds holding

Funds holding: 196 → 245 (+49)

11% more funds holding in top 10

Funds holding in top 10: 9 → 10 (+1)

9.22% less ownership

Funds ownership: 117.09% → 107.87% (-9.2%)

Holders
245
Holders Change
+49
Holders Change %
+25%
% of All Funds
3.52%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.14%
New
72
Increased
86
Reduced
62
Closed
23
Calls
$10.7M
Puts
$7.5M
Net Calls
+$3.21M
Net Calls Change
+$6.82M

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$142M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$140M
3
State Street
State Street
Massachusetts
+$60.2M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$53.8M
5
Bank of America
Bank of America
North Carolina
+$50M

Top Sellers

1
CAC
Cowen and Company
New York
-$210M
2
RI
RTW Investments
New York
-$29.2M
3
Morgan Stanley
Morgan Stanley
New York
-$27.9M
4
AG
Artal Group
Luxembourg
-$26.8M
5
Artisan Partners
Artisan Partners
Wisconsin
-$24.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$774M +$29.9M +689,729 +4%
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$488M -$12.3M -282,664 -3%
BlackRock
3
BlackRock
New York
$447M +$47.9M +1,104,406 +13%
Vanguard Group
4
Vanguard Group
Pennsylvania
$424M +$142M +3,283,202 +55%
RI
5
RTW Investments
New York
$374M -$29.2M -673,968 -8%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$323M +$140M +3,228,923 +85%
ACA
7
Avoro Capital Advisors
New York
$316M +$16.1M +370,000 +6%
RCM
8
RA Capital Management
Massachusetts
$289M +$39.1M +900,000 +17%
Janus Henderson Group
9
Janus Henderson Group
United Kingdom
$225M +$53.8M +1,239,323 +34%
State Street
10
State Street
Massachusetts
$216M +$60.2M +1,386,087 +42%
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$141M -$13.8M -317,608 -9%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$119M +$14.3M +328,606 +15%
CC
13
Casdin Capital
New York
$95.8M – – –
BC
14
Boxer Capital
California
$79.3M – – –
PCH
15
Polar Capital Holdings
United Kingdom
$70.8M +$18.6M +428,025 +38%
SL
16
Siren LLC
Connecticut
$66.2M +$62.5M +1,440,736 New
Bank of America
17
Bank of America
North Carolina
$61.7M +$50M +1,151,748 +602%
Artisan Partners
18
Artisan Partners
Wisconsin
$61.1M -$24.9M -572,786 -30%
D.E. Shaw & Co
19
D.E. Shaw & Co
New York
$50.9M +$16M +369,608 +50%
N
20
Nuveen
North Carolina
$48.6M -$6.52M -150,140 -12%
CAM
21
Cormorant Asset Management
Massachusetts
$48.2M +$27.1M +625,000 +147%
Norges Bank
22
Norges Bank
Norway
$48.1M +$45.4M +1,046,856 New
O
23
OrbiMed
New York
$48M +$14.7M +338,330 +48%
Charles Schwab
24
Charles Schwab
California
$45.5M +$8.55M +197,065 +25%
Northern Trust
25
Northern Trust
Illinois
$44.6M +$9.16M +211,059 +28%
1
2 3 4 5

RNAM Hedge Fund Activity: Q3 2024 in Review

245 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q3 2024, worth a combined $5.8B — up 27% from $4.57B a quarter earlier.

Buyers outnumbered sellers: 72 funds opened new RNAM positions and 23 closed out — a net gain of 49 holders — while 86 added to existing stakes and 62 trimmed.

The largest buyer was Vanguard Group, adding an estimated $142M. The largest seller was Cowen and Company, exiting entirely with an estimated $210M sold.

  • 245 institutional investors held Avidity Biosciences (RNAM) as of Q3 2024, up from 196 in Q2 2024.
  • Funds reported $5.8B of Avidity Biosciences stock for Q3 2024, up 27% quarter-over-quarter.
  • 72 funds opened new Avidity Biosciences positions in Q3 2024 and 23 closed out, a net change of +49 holders.
  • The largest Avidity Biosciences buyer in Q3 2024 was Vanguard Group, an estimated $142M added.
  • The largest Avidity Biosciences seller in Q3 2024 was Cowen and Company, an estimated $210M sold.

Based on aggregated 13F filings for Q3 2024.